For health systems & providers
Operationalize new revenue. Close the healthcare evidence gap.
An investment-light, fully managed data licensing partnership. OneMedNet will generate revenue for you with little to no investment.
Make your patients visible in the science shaping their care.
For health systems
Real-World Data.
Real-World Value.
OneMedNet operates the full lifecycle so your team can represent its patients, close evidence gaps and establish a non-clinical revenue stream without disrupting care delivery.
$0 upfront
Infrastructure, de-identification, curation, sponsor management and compliance are operated as a managed program.
Independent of clinical workflows
Revenue is tied to data richness, completeness and cohort match frequency — not staff time or clinical volume.
Value returns to your organization
A defined share flows back on a recurring cadence with transparent reporting.
Licensed for defined use. Never sold.
Every engagement limits use by contract, preserves audit rights and supports immediate termination for unauthorized use. Access controls, encryption and ongoing audits protect the program end to end.
Executive summary
Operationalize non-clinical revenue
Your clinical data holds meaningful value beyond internal use.
Investment-light model
No or minimal need to invest capital and OpEx.
Strengthen core franchise
Opportunities for augmented clinical decision-making and clinical trial engagement.
Attractive revenue share
A direct share of revenue whenever your data is licensed.
Why the opportunity exists
Data like yours is essential to closing evidence gaps
Global de-identified data market
~10% CAGR · Source: Coherent Market Insights
- 01
Assessing effectiveness, outcomes & safety
Real-World Evidence (RWE) and Health Economics Outcomes Research (HEOR).
- 02
Optimizing population health
Fill care gaps, optimize access and explore patient journeys.
- 03
Efficiently trialing promising therapies
Synthetic control groups.
- 04
Training data for AI foundation models
Inform clinical decision-making and administrative processes.
- 05
Ensuring the efficient flow of capital
Comparative effectiveness and forecasting.
The opportunity is expanding
The market is shifting toward health-system data
Increasing need for health-system data
Buyers want multimodal clinical data — medical records, diagnostic data, patient-reported outcomes. Health systems are strategically advantaged to supply it.
An expanding drug pipeline needs your data
Clinical trials are the gating factor for emerging therapies. Health-system data can vet and accelerate candidate identification and enrollment.
Others may be monetizing your data now
Payers, revenue cycle, clearinghouses and related companies monetize data — potentially yours. OneMedNet offers a path to recapture that value.
Build vs. partner
Why partnering makes sense for most health systems
A data business is its own discipline. A partner carries the cost, risk and complexity — without disrupting your operations.
Capital, expense & core competency
Data businesses require specialized talent, technology and operations, potentially costing millions. A partner defrays most of this.
Compliance
Significant privacy (HIPAA, state) and security (HITRUST) obligations. A partner shoulders most of these.
Reputational risk
Marketing your data yourself invites problems nobody wants. A partner shields you from legal and reputational risk.
Your data “as is” is not enough
Buyers need data assembled across many systems — de-identified, linked, cleansed and normalized. A partner does this for you.
Your data won’t sell itself
Awareness, qualification, proposals, selection and negotiation against numerous alternatives. A partner does this for you.
Data customers are needy
Post-sale support: traceability questions, fill-rate changes, SLAs, receivables. A partner does this for you.
Why OneMedNet
Preferred by health systems. Preferred by buyers.
Preferred by health systems
- Fully managed, end to end. Technology, security, de-identification, commercialization and delivery.
- Minimal IT. A lightweight, read-only gateway with no workflow changes.
- Strong data protection. Use is rigorously controlled by law and contract.
Preferred by buyers
- Better data. Multimodal, longitudinal clinical data for phenotyping and richer endpoints.
- Better acquisition model. Precise matching and curation on demand — no more, no less.
- Better ROI. More cost-effective research, less time to analysis-ready.
Multimodal data network
Imaging, EMR, lab, device and pharma linked at the patient level across 2,300+ facilities.
iRWD™ platform
AI-driven discovery, curation and delivery. License only the data needed, analytics-ready.
AI de-identification + curation
Multi-layer PHI removal (symbolic AI, NER, LLMs, OCR) with human QA. HIPAA Safe Harbor.
Revenue share for providers
Direct revenue share tied to data richness and match frequency. Zero operational burden.
Enterprise security & compliance
HITRUST r2, SOC 2 Type II, HIPAA. Full BAA coverage — OneMedNet owns compliance end to end.
Maximize your opportunity
Your specialty data depth is highly valued
Buyers pay a premium for high-burden therapeutic areas — when the data closes complex clinical evidence gaps.
| Specialty | Modalities sourced | Buyer demand |
|---|---|---|
| Oncology | CT / MR / PET, digital pathology, NGS genomics, labs, treatment & response, notes | RWE endpoints & biomarkers · AI tumor detection · Pharma external control arms |
| Cardiology | Echo, coronary CTA, cardiac MR, ECG waveforms, cath & procedures, meds | Device FFR / CAD validation · AI ECG & imaging models · RWE safety & outcomes |
| Women's Health | Mammography (multi-vendor), breast MR / US, OB ultrasound, screening history | AI detection, less device bias · RWE screening outcomes · Life science representation |
| Men's Health | Prostate MR, urologic imaging, pathology, PSA & labs over time | AI prostate detection · RWE screening & progression · Pharma & device studies |
| Neurology | Brain MR / CT, PET, EEG, cognitive assessments, longitudinal notes | AI neuro imaging · RWE neurodegeneration · Pharma trial enrichment |
| Metabolic & Endocrine | Labs (A1c, lipids), meds, vitals / flowsheets, CGM & wearable signals | RWE real-world effectiveness · HEOR payer outcomes · Pharma comparative studies |
Your multimodal breadth is highly valued
Medical records are essential, but incomplete. Adding patient-reported outcomes and diagnostic data drives more revenue for you.
EHR records
- Encounters & visit data
- Diagnoses & problem lists
- Procedures & interventions
- Medications & administrations
- Vitals & physical exams
- Clinical notes & documents
Patient-reported
- Outcomes & symptoms
- Functional status & QoL
- Satisfaction
- Treatment preferences
- Adherence
Diagnostic data
- Imaging DICOM & reports
- Lab results
- Genomics, molecular & omics
- Raw sensor feeds (ECG/EEG)
- Home & wearable devices
- In-clinic devices
Governance
Use is rigorously regulated by law and contract
We never sell data
OneMedNet licenses data only — for clearly defined, restricted use.
Use is highly regulated
HIPAA, state laws and the FTC apply. Re-identification and breach carry significant civil and criminal penalties.
Audit rights + kill switch
Every contract includes audit rights and immediate termination for any unauthorized or unlawful use.
Security by design
Technical, physical and administrative safeguards — access controls, encryption and ongoing audits.
What is de-identified data?
A patient's Protected Health Information (PHI) is removed exactly as prescribed by HIPAA. Once de-identified, re-identification is impermissible — and contractually prohibited.
What rights do patients have?
Under HIPAA, patients retain rights to privacy, access, inspection and to propose amendments. PHI may not be sold without patient permission; de-identification removes patient information entirely.